Metabolic analysis in drug discovery
Cárdenas, M.L.; Cornish-Bowden, A.
Science 288(5466): 618-619
2000
ISSN/ISBN: 0036-8075 PMID: 10798998 Document Number: 514978
A letter comments on the March 17 special issue on drug discovery. The letter points out that almost no direct mention was made of metabolism and, furthermore, that the new drug targets revealed by the Human Genome Project may simply be a new form of trial and error. A reply is published.
Document emailed within 1 workday
Related Documents
Kojima, H.; Okabe, T.; Nagano, T. 2013: Open innovation center for drug discovery: a research-supporting network for drug discovery Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(6): 327-332Fujita, Y. 2013: Innovation by TaNeDS (Take a New challenge of Drug diScovery) collaborative drug discovery project Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(2): 89-95
Harrigan, G.G. 2006: Metabolic profiling--IBC's inaugural meeting. Using metabolomics to accelerate drug discovery and development. 14-15 November 2005, Durham, NC, USA IDrugs: the investigational drugs journal 9(1): 28-31
Xu, J. 2004: Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA IDrugs: the investigational drugs journal 7(9): 839-840
Shen, Y. 2007: Discovery on Target 2007--CHI's Fifth Annual Conference. RNAi for Drug Discovery and Therapeutics IDrugs: the investigational drugs journal 10(12): 848-850
Young, S.S. 1999: Discovery 99: accelerate and improve the drug discovery process. 26-29 April 1999, San Diego, CA, USA IDrugs: the investigational drugs journal 2(7): 648-649
Chaudhary, R.; Balhara, M.; Jangir, D.Kumar.; Dangi, M.; Dangi, M.; Chhillar, A.K. 2019: In Silico Protein Interaction Network Analysis of Virulence Proteins Associated with Invasive Aspergillosis for Drug Discovery Current Topics in Medicinal Chemistry 19(2): 146-155
Kashyap, A.; Singh, P.Kumar.; Silakari, O. 2018: Counting on Fragment Based Drug Design Approach for Drug Discovery Current Topics in Medicinal Chemistry 18(27): 2284-2293
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Emilien, G.; Maloteaux, J.M. 1998: Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities International Journal of Clinical Pharmacology and Therapeutics 36(4): 181-194
Armetti, L. 1999: Round table: The Italian Pharmacology Society and the drug industry: new processes in drug discovery and the contribution of universities Bollettino chimico farmaceutico 138(11): 596-598
Bittner, B.; Mountfield, R.J. 2002: Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters Current Opinion in Drug Discovery and Development 5(1): 59-71
Williams, M. 2003: Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia Current Opinion in Investigational Drugs 4(1): 31-36
1996: Redesigning drug discovery Nature 384(6604 Suppl): 1-5
Wu, Y-Shan.; Lin, W-Hsing.; Hsu, J.T-A.; Hsieh, H-Pang. 2006: Antiviral drug discovery against SARS-CoV Current Medicinal Chemistry 13(17): 2003-2020
Bondy, S.S. 1998: The role of automation in drug discovery Current Opinion in Drug Discovery and Development 1(1): 116-119
Bleicher, K.H. 2002: Chemogenomics: bridging a drug discovery gap Current Medicinal Chemistry 9(23): 2077-2084
Honma, T. 2012: In silico drug discovery and SBDD Nihon Rinsho. Japanese Journal of Clinical Medicine 70 Suppl. 8: 326-330
McGowan, J.; Hoth, D. 1989: AIDS drug discovery and development Journal of Acquired Immune Deficiency Syndromes 2(4): 335-343
Murata, M. 2010: Discovery of an antiparkinsonian drug: zonisamide Rinsho Shinkeigaku 50(11): 780-782